Αποτελέσματα Αναζήτησης
Patients with mild-to-moderate disease who are at high risk for progression to severe COVID-19. One RCT compared treatment with three days of intravenous (IV) remdesivir (200 mg on day one followed by 100 mg on days two and three) initiated within 7 days of symptom onset or no remdesivir in unvaccinated patients [158].
12 Ιουλ 2024 · Pemivibart is an IV-infusion monoclonal antibody that is authorized for pre-exposure prevention of COVID-19 for individuals (12 years of age and older weighing at least 40 kg).
23 Μαρ 2021 · This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
6 Ιουν 2021 · The purpose of this document is to provide clinicians at The Johns Hopkins Hospital (JHH) and the Johns Hopkins Health System (JHHS) with guidance for pharmacologic treatment of inpatient and outpatient care of patients diagnosed with coronavirus disease 2019 (COVID-19).
5 Σεπ 2022 · Patients With Mild-to-Moderate Disease Who Are at High Risk for Progression to Severe Covid- 19. One RCT compared treatment with 3 days of IV remdesivir (200 mg on day 1 followed by 100 mg on days 2 and 3) initiated within 7 days of symptom onset or no remdesivir in unvaccinated patients [160].
Infusion pump: Infusion pumps are devices used to accurately deliver liquids through intravenous (IV) or epidural routes for therapeutic or diagnostic purposes. They provide greater accuracy than
7 Ιουλ 2023 · This resource is intended to serve as a guide on available outpatient COVID-19 treatment options, with links to FDA prescribing information, FDA Emergency Use Authorization, and guideline recommendations from national guideline-developing organizations, where available.
